Russian drugmaker Nizhpharm is launching a new oxymetazoline-based nasal spray, Snupoxy, on the domestic market, the company told GxP News. It is the first nasal spray in the decongestant category for rhinitis to combine this active ingredient with sea water.
The company said in a statement that oxymetazoline helps relieve nasal congestion, can start working within 25 seconds, and provides up to 12 hours of relief. The sea water component is intended to moisturise the mucous membrane and prevent dryness associated with oxymetazoline use.
The drug, developed by Nizhpharm’s pharmaceutical development laboratory, is being produced in a full cycle at the company’s plant in Nizhny Novgorod, the press release said. Nizhpharm’s Chief Executive Dmitry Isachenko stated that the spray was launched as part of a strategy to localize production of socially significant and in-demand medicines.
According to the State Register of Medicinal Products (GRLS), Snupoxy is manufactured using pharmaceutical substances supplied by Germany’s Siegfried PharmaChemikalien Minden and India’s CTX Lifesciences Private. The registry also shows that nine oxymetazoline-based drugs are already marketed in Russia—two as nasal drops and seven as sprays, including four versions of P&G Health Germany’s Nazivin (standard and for sensitive mucosa) in both forms.
